News

Dutch scientists have identified different genes in Staphylococcus aureus — a kind of bacteria carried in the nostrils — in either patients with PR3-ANCA vasculitis or with MPO-ANCA-positive vasculitis. The results suggest that the genes they found are relevant in causing and prolonging the disease. The study, “Genetic loci…

A review about the anti-neutrophil cytoplasmic antibody (ANCA) glomerulonephritis and vasculitis outlined the best way to characterize the different kinds of ANCA-associated disease in order to provide better treatment. The review, “ANCA Glomerulonephritis and Vasculitis,” was published in the Clinical Journal of the American Society…

Low levels of adenosine-regulating cell surface proteins on T-cells of patients with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis may contribute to autoimmunity, a new study suggests. The study, “Changes in CD73, CD39 and CD26 expression on T-lymphocytes of ANCA-associated vasculitis patients suggest impairment in adenosine generation and turn-over,”…

Doctors involved in treating children with antineutrophil cytpolasmic antibody (ANCA)-associated vasculitis (AAV) have revealed the unmet need for evidence-based treatment guidelines that improve the management and outcomes of their patients, a new international survey revealed. The study, “Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists…

In patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), Rituxan (rituximab) may lead to general decrease in antibody levels, increasing their risk for infections, finds a single-center retrospective study. The study, “Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis,” appeared in…

The U.S. Food and Drug Administration (FDA) has accepted for review the biologics license application  seeking approval of Truxima (CT-P10), Celltrion‘s biosimilar to Rituxan (rituximab), for the same indications as Rituxan. The FDA’s decision is expected by the first quarter of 2018. If approved, Truxima will become available for two…